The compact and versatile oxetane motifs have gained significant attention in drug discovery
and medicinal chemistry programs. This review presents an overview of the diverse …

Parkinson's disease (PD) is a devastating disease associated with accumulation of α-
synuclein (α-Syn) within dopaminergic neurons, leading to neuronal death. PD is …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial
Parkinson's disease (PD) and a risk factor for the sporadic form. Increased kinase activity …

LRRK2 is one of the most promising drug targets for Parkinson's disease. Though type I
kinase inhibitors of LRRK2 are under clinical trials, alternative strategies like type II inhibitors …

In recent years, drug design has been revolutionized by the application of deep learning
techniques, and molecule generation is a crucial aspect of this transformation. However …

The increasing prevalence of Parkinson disease (PD) highlights the need to develop
interventions aimed at slowing or halting its progression. As a result of sophisticated disease …

Vestigial dopaminergic cells in PD have selectivity for a sub-class of hypersensitive neurons
with the nigrostriatal dopamine (DA) tract. DA is modulated in pre-synaptic nerve terminals to …

Mutations in LRRK2 (encoding leucine‐rich repeat kinase 2 protein, LRRK2) are the most
common genetic risk factors for Parkinson's disease (PD), and increased LRRK2 kinase …

The elevated activity of leucine-rich repeat kinase 2 (LRRK2) is implicated in the
pathogenesis of Parkinson's disease (PD). The quest for effective LRRK2 inhibitors has …

As Parkinson's disease (PD) progresses, there are multiple biomarker changes, and sex and
genetic variants may influence the rate of progression. Data‐driven, long‐term disease …